Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-7888 for AML in First Complete Remission
NCT04747002Phase 2Unknown
- Sponsor
- The University of Osaka
- Start
- Jun 2020
- Primary completion
- Mar 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of adegramotide + nelatimotide in acute myeloid leukemia (AML), sponsored by The University of Osaka. Status: unknown.
02
Drugs
adegramotide + nelatimotide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04747002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747002.